| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/28/2002 | WO2002016352A1 Quinazoline derivatives |
| 02/28/2002 | WO2002016349A1 4-, 5-, 6- and 7-indole derivatives useful for the treatment of cns disorders |
| 02/28/2002 | WO2002016347A1 Active metabolite of gepirone |
| 02/28/2002 | WO2002016344A1 Tetrahydropyran derivatives as nk-1 receptor antagonists |
| 02/28/2002 | WO2002016343A1 Tetrahydropyran derivatives as nk-1 receptor antagonists |
| 02/28/2002 | WO2002016342A1 Method for the preparation of citalopram |
| 02/28/2002 | WO2002016341A1 Method for the preparation of citalopram |
| 02/28/2002 | WO2002016340A1 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 02/28/2002 | WO2002016337A1 Tricyclic compounds and pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016333A2 Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease |
| 02/28/2002 | WO2002016324A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 02/28/2002 | WO2002016321A1 Prodrugs to nmda receptor ligands |
| 02/28/2002 | WO2002016319A1 Novel thiourea compounds and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016318A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016316A1 10-ARYL-11-HBENZO [b]FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE |
| 02/28/2002 | WO2002016314A1 Substituted polyamine compounds |
| 02/28/2002 | WO2002016313A2 Integrin receptor inhibitors |
| 02/28/2002 | WO2002016311A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 02/28/2002 | WO2002015941A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 02/28/2002 | WO2002015937A2 Pharmaceutical composition for the systematic administration of pharmacologically active ingredients containing polyol fatty acid esters |
| 02/28/2002 | WO2002015934A1 Preventives and remedies for central nervous system diseases |
| 02/28/2002 | WO2002015933A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
| 02/28/2002 | WO2002015932A1 Methods for treating demyelinating diseases |
| 02/28/2002 | WO2002015923A1 Orally administered peptides to ameliorate atherosclerosis |
| 02/28/2002 | WO2002015922A2 New uses for amino acid anticonvulsants for treatment of pain |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015917A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 02/28/2002 | WO2002015906A1 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon |
| 02/28/2002 | WO2002015903A2 Novel pharmaceutical composition for administering n-0923 |
| 02/28/2002 | WO2002015892A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 02/28/2002 | WO2002015891A2 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| 02/28/2002 | WO2002015890A1 Transdermal therapeutic system |
| 02/28/2002 | WO2002015889A1 Transdermal therapeutic system for treating restless-legs-syndrome |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015879A1 A method of treating a systemic disease |
| 02/28/2002 | WO2002015878A1 Aqueous suspension preparations |
| 02/28/2002 | WO2002015867A1 Use of beta-mannosylglycerate and derivatives in cosmetic and dermatological formulations |
| 02/28/2002 | WO2002015846A2 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/28/2002 | WO2002015662A2 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| 02/28/2002 | WO2001095924A3 Method for treating a movement disorder |
| 02/28/2002 | WO2001087887A3 Neuroprotective and anti-proliferative compounds |
| 02/28/2002 | WO2001085779A3 Protein complexes and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001083747A3 Prion proteins and their uses |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001075064A3 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 02/28/2002 | WO2001074378A3 Promoting cell growth by inhibiting enabled proteins or their ligands |
| 02/28/2002 | WO2001073029A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/28/2002 | WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 02/28/2002 | WO2001058936A3 Constructs for delivery of therapeutic agents to neuronal cells |
| 02/28/2002 | WO2001049309A3 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 02/28/2002 | WO2001045714A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001045685A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001042474A3 Interferon-like molecules and uses thereof |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001041769A3 Combination of cyamemazine and an atypical neuroleptic |
| 02/28/2002 | WO2001031029A3 Human sphingosine kinase gene |
| 02/28/2002 | WO2001027254A3 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 02/28/2002 | WO2001025469A3 Method for preparing steroids modified by yeast fermentation |
| 02/28/2002 | WO2001017614A3 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 02/28/2002 | WO2001005422A3 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/28/2002 | US20020026062 Method for the preparation of citalopram |
| 02/28/2002 | US20020026059 Use as microbicides in crop protection |
| 02/28/2002 | US20020026057 1-(2-(2-naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6 -tetrahydropyridine hydrochloride; dissolved by heating in a solvent an alcohol, keton, DMSO or ethyl acetate solvent |
| 02/28/2002 | US20020026050 Thrombin receptor antagonists |
| 02/28/2002 | US20020026040 And isolated nucleic acids containing coding regions of genes encoding such proteins; for use in gene therapy treatment of cancer, autoimmune diseases, viral diseases |
| 02/28/2002 | US20020026032 3, 5-Dioxa-12-azawurtzitane compound and process of preparing same |
| 02/28/2002 | US20020025985 Apoptosis inhibitor |
| 02/28/2002 | US20020025983 Anticoagulant mixture; cardiovascular disordrs; premenstrual disorders; bone disorders |
| 02/28/2002 | US20020025982 Method for the preparation of citalopram |
| 02/28/2002 | US20020025970 Materials and methods for the treatment of gastroesophageal reflux disease |
| 02/28/2002 | US20020025967 Antiserotinone agents |
| 02/28/2002 | US20020025966 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 02/28/2002 | US20020025965 Antiserotonine agents |
| 02/28/2002 | US20020025958 Psychological disorders |
| 02/28/2002 | US20020025957 Anticoagulants, cardiovascular disorders |
| 02/28/2002 | US20020025956 Nervous system, psychological disorders |
| 02/28/2002 | US20020025955 Substituted lactams as inhibitors of A beta protein production |
| 02/28/2002 | US20020025953 Using oil |
| 02/28/2002 | US20020025949 Anti-epileptogenic agents |
| 02/28/2002 | US20020025935 Antiinflammatory agents; autoimmune diseases; central nervous system disorders |
| 02/28/2002 | US20020025558 Human MAD proteins and uses thereof |
| 02/28/2002 | US20020025341 Controlled release formulation of divalproex sodium |
| 02/28/2002 | US20020025317 For therapy and prophylaxis of pathological condition associated with expression of Interelukin-12 and/or Interleukin-18, including excessive or inappropriate amounts of those cytokines |
| 02/28/2002 | US20020025304 Novel interferon for the treatment of multiple sclerosis |
| 02/28/2002 | DE10040016A1 Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel New beta-amyloid inhibitors, processes for their preparation and their use as medicaments |
| 02/28/2002 | CA2740815A1 New uses for amino acid anticonvulsants |
| 02/28/2002 | CA2456008A1 Stem cell differentiation |
| 02/28/2002 | CA2420550A1 Peptide with effects on cerebral health |
| 02/28/2002 | CA2420289A1 10-aryl-11-hbenzo [b]fluorene derivatives and analogs for medicinal use |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/28/2002 | CA2420235A1 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon |
| 02/28/2002 | CA2420190A1 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2420179A1 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | CA2420071A1 Process for the preparation of neutrophil inhibitory factor |